KANDLELIT-014: Assessing targeted medicines for the treatment of advanced solid cancers with a KRAS G12C mutationA Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination With Cetuximab, in Participants With KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)

Trial purpose

Cancer treatment

Tumor type

Multi-Cancer

Age

18+

Trial acronym

KANDLELIT-014

Summary

Researchers want to learn if a medicine called calderasib targeted therapy given alone, or with cetuximab targeted therapy, can treat certain advanced solid tumours in people with the KRAS G12C mutation. 

You may be eligible if you have a locally advanced, unresectable, or metastatic solid cancer (excluding colorectal cancer) that has progressed on, or after, standard of care systemic treatment. Your cancer should have the KRAS G12C mutation.

The goal of this study are to learn:

• How many people have the cancer respond (get smaller or go away) when treated with calderasib alone or with cetuximab, and how these responded compare.
• About the safety of calderasib alone or with certuximab, and if people tolerate the treatments.

Eligible participants will be randomly allocated (by chance) to receive one of two treatments:

• Calderasib alone, as an oral tablet.
• Calderasib orally plus cetuximab intravenous (IV) infusion.

Conditions

This trial is treating people with solid cancers (excluding bowel cancer) with a KRAS G12C mutation